November 3, 2008 – PETNET Solutions, a wholly-owned subsidiary of Siemens Medical Solutions USA, and Covidien have entered into a co-marketing agreement to offer a combined portfolio of high-energy and low-energy radioisotopes to the nuclear medicine community in the U.S.
PETNET and Covidien Imaging Solutions will create a network of nuclear imaging product offerings to expand customer access to a wider range of products, including molecular imaging agents, or radiopharmaceuticals, designed to illuminate conditions, such as cancer or heart disease, during imaging procedures. The agreement brings together Covidien’s single photo emission computed tomography (SPECT) products and PETNET’s positron emission tomography (PET) products.
“This agreement further validates the efforts Covidien has undertaken in recent years to enhance our reputation as a valued supplier of essential diagnostic products,” said Steve Hanley, president, Imaging Solutions, Covidien. “With the agreement we are positioned to offer our nuclear medicine customers expanded access to both product lines to help them provide better patient diagnostic services. It also provides PETNET with access to our extensive SPECT product offerings.”
Additionally, this agreement allows both companies to offer customers enhanced service, expertise and product sourcing options.
“We are pleased to work in tandem with Covidien to offer radiopharmaceuticals for both PET and SPECT imaging. This agreement strengthens Siemens offerings in radiopharmaceutical distribution and contributes to the availability of molecular imaging to patients nationwide,” said Michael Reitermann, CEO, Molecular Imaging, Siemens Healthcare.
For more information: www.usa.siemens.com/healthcare and www.covidien.com